Edition:
United States

Orexo AB (ORX.ST)

ORX.ST on Stockholm Stock Exchange

37.40SEK
11:29am EST
Change (% chg)

1.40kr (+3.89%)
Prev Close
36.00kr
Open
36.80kr
Day's High
37.60kr
Day's Low
36.50kr
Volume
101,197
Avg. Vol
107,602
52-wk High
69.00kr
52-wk Low
32.30kr

ORX.ST

Chart for ORX.ST

About

Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects... (more)

Overall

Beta: 1.54
Market Cap(Mil.): kr1,243.27
Shares Outstanding(Mil.): 34.54
Dividend: --
Yield (%): --

Financials

  ORX.ST Industry Sector
P/E (TTM): -- 29.74 30.35
EPS (TTM): -1.31 -- --
ROI: -5.70 15.90 15.27
ROE: -15.19 17.00 16.60

Orexo, Actavis split win on Zubsolv patents

A split patent decision by a federal judge in Delaware will allow Swedish pharmaceutical firm Orexo AB and its U.S. subsidiary to hold off generic competition to its opioid-addiction drug Zubsolv for three more years, but not the 16 years the company sought.

Nov 17 2016

BRIEF-Orexo says may appeal part of U.S. patent ruling

* Favorable outcome from Zubsolv patent infringement litigation against Actavis

Nov 16 2016

BRIEF-Orexo Q3 net earnings 36.0 mln crowns

* Says our ambition is to win a disproportionate share of new patients in regions where Zubsolv is reimbursed and have market access comparable to our main branded competitors

Oct 20 2016

BRIEF-U.S. FDA approves Orexo's low dose Zubsolv for treatment of patients with opioid dependence

* U.S. FDA approves Orexo's low dose zubsolv buprenorphine and naloxone sublingual tablets (CIII)

Oct 06 2016

BRIEF-Orexo says receives FDA approval for Zubsolv

* Says it has received approval from the US Food and Drug Administration (FDA) of a new unique low dose, 0.7mg/0.18 mg, tablet of Zubsolv (buprenorphine/naloxone) sublingual tablet (CIII) for the treatment of opioid dependence

Oct 06 2016

BRIEF-Orexo Q2 net earnings in line with expectations

* Says effective July 1st Zubsolv is only preferred buprenorphine/naloxone product within largest fee for service (ffs) medicaid program in U.S., state of Maryland

Jul 12 2016

BRIEF-Orexo signs license agreement with Mundipharma, which obtains ex-US global rights to Zubsolv

* signs license agreement with Mundipharma, which obtains ex-us global rights to Zubsolv

Jun 30 2016

Earnings vs. Estimates